IPP Bureau
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
By IPP Bureau - August 05, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular study
By IPP Bureau - August 05, 2024
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Concerted efforts of individual and institutions needed for organ donation and transplantation: MoS Health Anupriya Patel
By IPP Bureau - August 04, 2024
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
AbbVie completes acquisition of Cerevel Therapeutics
By IPP Bureau - August 03, 2024
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion
By IPP Bureau - August 03, 2024
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Supriya Lifescience names Dr. Saloni Wagh as MD
By IPP Bureau - August 03, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
By IPP Bureau - August 03, 2024
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Alembic receives USFDA final approval for Nelarabine Injection, 250 mg/50 mL
By IPP Bureau - August 03, 2024
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Aster DM Healthcare posts Q1 FY25 PAT at Rs. 74 Cr
By IPP Bureau - August 02, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr
By IPP Bureau - August 02, 2024
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
By IPP Bureau - August 02, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
GlaxoSmithKline Pharmaceuticals reports Q1 FY25 PAT at Rs. 182 Cr
By IPP Bureau - August 02, 2024
Strong topline growth driven by solid performance across key brands.
Shilpa Pharma Lifesciences received CEP from EDQM for ursodeoxycholic acid
By IPP Bureau - August 01, 2024
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Lupin receives approval from USFDA for Emtricitabine and Tenofovir Alafenamide Tablets
By IPP Bureau - August 01, 2024
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
